Cargando…
A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy
BACKGROUND: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared. METHODS: This single-center retrospective cohort study of inpatients with steroid-refractory ASUC who receive...
Autores principales: | Vasudevan, Abhinav, Arachchi, Asiri, Scanlon, Cian, Greenhalgh, Jarrod, Van Langenberg, Daniel R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354298/ https://www.ncbi.nlm.nih.gov/pubmed/30728932 http://dx.doi.org/10.1177/2040622319825595 |
Ejemplares similares
-
Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
por: Con, Danny, et al.
Publicado: (2022) -
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009) -
Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab
por: De Cristofaro, Elena, et al.
Publicado: (2022) -
Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008) -
Mucosal healing in ulcerative colitis: surveillance or colectomy?
por: Andrisani, Gianluca, et al.
Publicado: (2013)